Zosuquidar is a compound of antineoplastic drug candidates currently under development. It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.
Investigated for use/treatment in leukemia (myeloid) and myelodysplastic syndrome.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.